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ABSTRACT
Background: Emerging evidence suggests potential links between
some dietary fatty acids and improved fertility, because specific
fatty acids may affect prostaglandin synthesis and steroidogenesis.
Objective: The objective of this exploratory study was to evaluate
associations between total and specific types of dietary fat intake
and 1) hormone concentrations and 2) the risk of sporadic anovu-
lation in a cohort of 259 regularly menstruating women in the Bio-
Cycle Study.
Design: Endogenous reproductive hormones were measured up to 8
times/cycle for up to 2 cycles, with visits scheduled with the use of
fertility monitors. Dietary intake was assessed with up to four 24-h
recalls/cycle. Linear mixed models and generalized linear models were
used to evaluate the associations between dietary fatty acids and both
reproductive hormone concentrations and ovulatory status. All models
were adjusted for total energy intake, age, body mass index, and race.
Results: Relative to the lowest levels of percentage of energy
from total fat, the highest tertile was associated with increased
total and free testosterone concentrations (total: percentage
change of 4.0%; 95% CI: 0.7%, 7.3%; free: percentage change of
4.1%; 95% CI: 0.5%, 7.7%). In particular, the percentage of
energy from polyunsaturated fatty acids (PUFAs) in the highest
tertile was associated with increases in total and free testosterone
(total: percentage change of 3.7%; 95% CI: 0.6%, 6.8%; free:
percentage change of 4.0%; 95% CI: 0.5%, 7.5%). The PUFA
docosapentaenoic acid (22:5n–3) was not significantly associated
with testosterone concentrations (P-trend = 0.86 in energy sub-
stitution models) but was associated with increased progesterone
and a reduced risk of anovulation (highest tertile compared
with the lowest tertile: RR: 0.42; 95% CI: 0.18, 0.95). Fat in-
takes were not associated with other reproductive hormone
concentrations.
Conclusions: These results indicate that total fat intake, and PUFA
intake in particular, is associated with very small increases in
testosterone concentrations in healthy women and that in-
creased docosapentaenoic acid was associated with a lower risk of
anovulation. Am J Clin Nutr doi: 10.3945/ajcn.115.119321.
Keywords: dietary fats, estradiol, menstrual cycle, ovulation,
testosterone
INTRODUCTION
A growing body of literature suggests that dietary and lifestyle
factors play an important role in various biological processes
involved in human reproduction. Dietary fat intakes in particular
are hypothesized to affect fertility and pregnancy outcomes,
likely through prostaglandin synthesis and steroidogenesis (1, 2).
Although animal studies have shown the importance of dietary
fatty acid composition on ovulation and fertility (3–5), only a few
studies to date have evaluated the association between fat intake
and menstrual cycle function in humans (6–11). Some evidence
suggests that increases in total and specific types of dietary fatty
acid intake improve menstrual cycle function (6–11), although
other studies observed no associations between fat intakes and
estradiol concentrations (12–20). Less is known, however, with
regard to the association between fat intakes and androgen
concentrations and ovulation, although a previous study showed
improvements in metabolic and endocrine characteristics in re-
sponse to changes in dietary macronutrient intake (lowering
carbohydrates and increasing fat intake) in women with poly-
cystic ovarian syndrome (21), which may point to potential di-
etary interventions to improve fertility. Previous studies have
typically been limited by small sample sizes, inadequate timing
of sample collection to cycle phase, and failure to evaluate
ovulatory function among healthy women. Moreover, the eval-
uation of specific types of fatty acids may be relevant given that
other reproductive outcomes have been differentially influenced
by type of fatty acids; for example, PUFAs have been shown to
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reduce preterm birth (1), whereas trans fats have been associated
with ovulatory infertility (22) and endometriosis (23). There-
fore, the objective of this exploratory study was to evaluate
associations between total and specific types of dietary fat intake
and both hormone concentrations and sporadic anovulation in
a cohort of 259 regularly menstruating women in the BioCycle
Study.
METHODS
Design and study population
The BioCycle Study (2005–2007) was a prospective cohort of
259 regularly menstruating, healthy volunteers, aged 18–44 y,
recruited from western New York. Details of the study design
are described elsewhere (24). Exclusion criteria included the
following: current use of hormonal contraceptives [or use during
the previous 3 mo for short-acting (e.g., oral contraceptive pills)
and 12 mo for longer-acting hormonal contraceptives (e.g.,
Norplant (Wyeth-Ayerst), Depo-Provera (Pfizer), or hormonal
intrauterine device)], pregnancy or breastfeeding in the past
6 mo, and diagnosis of certain chronic conditions, including
a history of menstrual and ovulation disorders or uterine ab-
normalities, such as uterine fibroids. Women with a self-reported
BMI (kg/m2) of ,18 or .35 at screening were excluded, as
were women who were planning to restrict their diet over the
study period or who consumed a diet high in phytoestrogens.
The University at Buffalo Health Sciences Institutional Review
Board approved the study, and served as the institutional review
board designated by the NIH under a reliance agreement. All of
the participants provided written informed consent.
Participants were followed for 1 (n = 9) or 2 (n = 250)
menstrual cycles (Supplemental Figure 1). Blood samples were
collected for hormonal assessment during the following phases:
second day of menstruation, mid- and late follicular phase,
luteinizing hormone (LH)9 and follicle stimulating hormone
(FSH) surges and predicted ovulation, and early, mid-, and late
luteal phase. Fertility monitors (Clearblue Easy Fertility Moni-
tor; Inverness Medical) were used to determine the timing of
midcycle visits, with other visits scheduled according to an al-
gorithm that took each woman’s reported cycle length history
into consideration (25). Women were highly compliant with the
study protocol; 94% of participants completed at least 7 clinic
visits/cycle.
Dietary assessment
Dietary intake was assessed 4 times/cycle by using a 24-h
dietary recall on the same days as the sample collection for the
menstruation, midfollicular, ovulation, and midluteal phases, for
up to 8 recalls over 2 cycles. Dietary intake data were collected
and analyzed by using the Nutrition Data System for Research
software version 2005 developed by the Nutrition Coordinating
Center, University of Minnesota, Minneapolis, Minnesota. The
percentage of energy from total fats, MUFAs, PUFAs [including
v-3s and v-6s, and specifically the PUFAs a-linolenic acid
(18:3n–3), EPA (20:5n–3), docosapentaenoic acid (22:5n–3),
and DHA (22:6n–3)], SFAs, and trans fats were calculated from
the 24-h dietary recalls. Because the consumption of total fat
and specific types of fat did not significantly change across the
cycle, we calculated average fat intakes/cycle for this analysis
(including up to 4 recalls/cycle). The majority of women
completed 4 dietary recalls/cycle (87%). For all statistical
models, we used the average cycle-specific fat intake as the
exposure of interest.
Reproductive hormones
Reproductive hormones were measured in fasting serum blood
samples collected at each cycle visit (8 visits/cycle for 2 cycles) at
the Kaleida Health Center for Laboratory Medicine (Buffalo,
New York). Total estradiol, FSH, LH, progesterone, and sex
hormone–binding globulin (SHBG) were measured by using
solid-phase competitive chemiluminescent enzymatic immuno-
assays by Specialty Laboratories on a DPC Immulite 2000
analyzer (Siemens Medical Solutions Diagnostics). Total
testosterone concentrations (ng/dL) were determined by liquid
chromatography/tandem mass spectrometry with the use of
a Shimadzu Prominence Liquid Chromatogram (Shimadzu
Scientific Instruments) with an ABSceix 5500 tandem mass
spectrometer (Sciex). Increased sensitivity was obtained by the
use of mobile phase B (100% acetonitrile) with a low standard
of 4 ng/dL added to the standard curve. Calculations of free (i.e.,
bioavailable) estradiol and testosterone, and the free androgen
index (the ratio of total testosterone to SHBG, multiplied by
100), were performed via standardized methods (26, 27). Across
the study period, the CVs for these tests reported by the labo-
ratory were ,10% for estradiol and SHBG, ,5% for LH and
FSH, ,14% for progesterone, and ,7% for total testosterone.
Sporadic anovulatory cycles were defined as cycles with pro-
gesterone concentrations #5 ng/mL and no observed serum LH
peak during the later cycle visits. Specifically, the timing of the LH
peak in relation to the peak progesterone measurements was used
to inform whether an adequate number of serum samples during
the last half of the cycle were obtained to assess an increase in
progesterone and evidence of ovulation. On the basis of this al-
gorithm, 42 of the 509 cycles (8.3%) in this study were classified
as anovulatory (28 women had a single anovulatory cycle and 7
women had 2 anovulatory cycles during the study period) (28).
Covariate assessment
Participants completed questionnaires and provided information
on age, race, lifestyle, and reproductive and health history at
baseline.Weight and height weremeasured by trained research staff
using standardized protocols and were used to calculate BMI. In
addition, women completed the International Physical Activity
Questionnaire long-form 2002, fromwhich high, moderate, and low
physical activity categories were calculated on the basis of standard
International Physical Activity Questionnaire cutoffs (29). All of
the covariates assessed had at least a 94% response rate.
Statistical analysis
Descriptive statistics were calculated for demographic and
lifestyle characteristics, for mean dietary intakes across the study
9Abbreviations used: FSH, follicle stimulating hormone; LH, luteinizing
hormone; SHBG, sex hormone–binding globulin.
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(including up to 8 recalls/participant), and mean hormone con-
centrations across the study (including up to 16 measurements/
participant) and compared between tertiles of percentage of
energy from total fat intake averaged over the study period. Exact
chi-square tests and ANOVAs were used to test for associations
between demographic variables and tertiles of percentage of
energy from total fat intake.
Linear mixed models with random intercepts were used to
evaluate the association between average dietary fat intake (as
a percentage of energy for each type of fat) across the cycle
(averages calculated on the basis of up to 4 recalls/cycle) and
log serum concentrations of estradiol, free estradiol, FSH, LH,
luteal progesterone, SHBG, testosterone, free testosterone, and
the free androgen index at each cycle visit. The models took
repeated measures into account and included up to 16 hormone
concentrations/participant (up to 8/cycle). Fat intake was eval-
uated in tertiles, and trend tests were calculated by using the
median intake of fat in each tertile as a continuous variable.
Results are presented as percentage changes with 95% CIs. The
first model was adjusted for age, total energy intake, BMI, and
race and represents a total energy substitution model. This model
can be interpreted as the effect of increasing the percentage of
energy from fat (or each type of fat) and reducing the intake from
all other sources of energy by the same amount while keeping
calories constant. To evaluate the association of the substitution
of carbohydrates with intake of fat (or each type of fat), we further
fit a carbohydrate substitution model. Specifically, this model
additionally adjusted for the remaining types of fat (SFAs,
MUFAs, PUFAs, and trans fats) and protein intake. This model
can be interpreted as the effect of increasing the percentage of
energy intake from fat (or each type of fat) in place of carbo-
hydrates while keeping total calories constant. We further
evaluated the association between substituting one type of fat for
another by modeling the intake of specific fats as continuous
variables and calculating the difference in coefficients and the
covariance matrix to estimate CIs (30). Multivariable RR esti-
mation by Poisson regression with robust error variance was
used to estimate RRs and 95% CIs for the associations between
average dietary fat intake across the cycle and anovulation
(cycle was the unit of analysis). The total energy substitution,
carbohydrate substitution, and fat-by-fat substitution models
were likewise evaluated. Physical activity, smoking, and addi-
tional measures of dietary intake, including fiber, were consid-
ered as potential covariates but did not appreciably alter the
estimates. SAS version 9.4 (SAS Institute) was used for all
statistical analyses.
RESULTS
Overall, women in the BioCycle Study were young (mean age:
27.3 y), of healthy weight (mean BMI: 24.1), physically active
(moderate to high physical activity: 90.3%), and nonsmokers
(96.1%) (Table 1). Smokers were more likely to be in the middle
or upper tertile of total fat intake. Total fat intake as a percentage
of energy was not associated with age, BMI, physical activity,
race, education, marital status, parity, or past oral contraceptive
use. Women in the highest tertile of percentage of energy from
fat also had a significantly higher mean percentage of energy
from SFAs, MUFAs, PUFAs, v-3s, v-6s, trans fat, and total
energy, but lower mean percentage of energy from carbohy-
drates and fiber intake. Women in this study had, on average,
33.9%, 15.7%, 50.8%, and 1.0% of energy from fat, protein,
carbohydrates, and alcohol, respectively. Within-woman CVs
for PUFAs, v-3s, marine v-3 PUFAs, and the PUFAs a-linolenic
acid, EPA, docosapentaenoic acid, and DHA were 77%, 59%,
37%, 61%, 34%, 45%, and 36%, respectively.
Total fat intake, in particular of PUFAs, was significantly and
positively associated with total and free testosterone concen-
trations, and a-linolenic acid was positively associated with free
testosterone and the free androgen index (P-trend , 0.05 for
both total energy substitution and carbohydrate substitution
models for each association listed; Table 2). These associations
were consistent for both the total energy substitution model
(total fat and total testosterone association: highest compared
with lowest tertile: 4.0% change; 95% CI: 0.7%, 7.3%) and the
carbohydrate substitution model (total fat and total testosterone
association: highest compared with lowest tertile: 4.2% change;
95% CI: 0.9%, 7.6%). Thus, increases in total fat or PUFAs,
either in place of all other energy sources or carbohydrates in
particular, were associated with increases in testosterone.
Marine v-3 PUFAs (EPA, docosapentaenoic acid, and DHA)
were associated with increases in luteal-phase progesterone
concentrations. Specifically, intakes of these fatty acids in the
third tertile compared with the first tertile were associated with
significant increased progesterone concentrations in the carbo-
hydrate substitution models (P-trend , 0.05 for all models;
Table 2). Similar results were obtained in the energy substitution
models, with significant trends observed between each marine
v-3 PUFA and progesterone, although the association between
the third and first tertile was not significant for DHA. There was
also a significant trend observed between increasing DHA in-
takes and increased total estradiol in the energy substitution
model (P-trend = 0.04; Table 2), and similarly, between v-3s and
LH concentrations in the energy substitution model (P-trend = 0.04;
Table 2). No other associations were observed between
fat intakes and estradiol, progesterone, LH, or FSH concentra-
tions. Overall, the substitution of trans fat or v-3s for other
types of fat was not associated with reproductive hormone
concentrations (Table 3).
Total fat, SFA, MFA, and PUFA intakes when considered as
percentage of energy from fat were not associated with the risk of
a sporadic anovulatory cycle in this study in the total energy
substitution, carbohydrate substitution, or fat-by-fat substitution
models (Table 4). However, we did observe that cycles in which
women consumed docosapentaenoic acid in the second and third
tertiles of intake had a significantly reduced risk of being an-
ovulatory (RR for tertile 3 compared with tertile 1: 0.42; 95%
CI: 0.18, 0.95) in the carbohydrate substitution models. This
association was marginally significant in the total energy sub-
stitution models (RR for tertile 3 compared with tertile 1: 0.53;
95% CI: 0.27, 1.05; P = 0.07).
DISCUSSION
We observed that percentages of energy from total fat, total
PUFAs, and a-linolenic acid were associated with modest in-
creases in testosterone concentrations but not with estradiol or
anovulation in a cohort of regularly menstruating women. In
addition, marine v-3 fatty acids were associated with increased
progesterone concentrations and docosapentaenoic acid was
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associated with a decreased risk of anovulation. These associ-
ations remained significant even after adjustment for other fac-
tors related to both hormone concentrations and anovulation.
These findings highlight the potential role of fatty acids in an-
drogen synthesis, although the clinical implications of these
subtle associations between dietary fat intakes and testosterone
concentrations are unknown.
Our findings of increased testosterone in response to higher fat
intakes are consistent with a few small studies that found lower
testosterone or lower dehydroepiandrosterone sulfate in women
TABLE 1
Description of the study cohort by tertile of average percentage of energy from total fat intake across the study period1
Tertile of total fat intake
Overall 1: 18.3–31.8% of energy 2: .31.8–36.0% of energy 3: .36.0–49.2% of energy P2
Women, n 259 86 87 86
Demographic characteristics
Age, y 27.3 6 8.23 26.2 6 7.9 27.3 6 8.0 28.5 6 8.6 0.17
BMI, kg/m2 24.1 6 3.9 23.9 6 3.9 23.6 6 3.7 24.8 6 4.0 0.11
Physical activity, n (%) 0.71
Low 25 (10) 9 (11) 8 (9) 8 (9)
Moderate 92 (35) 31 (36) 35 (40) 26 (30)
High 142 (55) 46 (53) 44 (51) 52 (60)
Race, n (%) 0.15
White 154 (60) 45 (52) 51 (58) 58 (67)
Black 51 (20) 16 (19) 19 (22) 16 (19)
Other 54 (20) 25 (29) 17 (20) 12 (14)
High school education or less, n (%) 33 (13) 11 (13) 10 (11) 12 (14) 0.87
Current smoker, n (%) 10 (4) 0 (0) 4 (5) 6 (7) 0.03
Married, n (%) 66 (25) 23 (27) 21 (24) 22 (26) 0.92
Nulliparous, n (%) 187 (72) 63 (73) 62 (71) 62 (72) 0.89
Past OC use, n (%) 140 (54) 43 (50) 51 (59) 46 (53) 0.79
Dietary intake
Percentage of energy
Fat 33.9 6 5.4 28.0 6 3.1 33.8 6 1.1 39.8 6 3.0 ,0.0001
Saturated fat 11.6 6 2.5 9.3 6 1.9 11.7 6 1.6 13.6 6 2.0 ,0.0001
Monounsaturated fat 12.6 6 2.4 10.3 6 1.6 12.5 6 1.0 14.9 6 1.6 ,0.0001
Polyunsaturated fat 7.0 6 1.6 6.1 6 1.3 6.9 6 1.5 8.1 6 1.5 ,0.0001
v-3s 0.8 6 0.3 0.7 6 0.3 0.8 6 0.2 0.8 6 0.2 ,0.0001
v-6s 6.3 6 1.5 5.4 6 1.1 6.2 6 1.3 7.2 6 1.3 ,0.0001
trans Fat 2.3 6 0.8 1.8 6 0.6 2.3 6 0.7 2.7 6 0.8 ,0.0001
Protein 15.7 6 2.9 15.4 6 2.7 15.9 6 3.3 15.9 6 2.7 0.51
Carbohydrates 50.8 6 7.1 57.8 6 4.8 50.5 6 4.2 44.3 6 4.5 ,0.0001
Alcohol 1.0 6 2.0 0.6 6 1.3 1.3 6 2.5 1.2 6 1.8 0.03
Total energy intake, kcal 1607.4 6 354.3 1512.9 6 311.6 1634.6 6 341.6 1674.6 6 389.4 0.007
Fiber, g/d 13.6 6 5.6 15.2 6 6.9 13.3 6 4.7 12.2 6 4.3 0.002
v-3s, g/d 1.4 6 0.5 1.1 6 0.5 1.4 6 0.5 1.6 6 0.6 ,0.0001
a-Linolenic acid, g/d 1.3 6 0.5 1.0 6 0.4 1.3 6 0.5 1.5 6 0.5 ,0.0001
Marine PUFAs, g/d 0.10 6 0.13 0.10 6 0.15 0.11 6 0.12 0.11 6 0.11 0.92
EPA, g/d 0.02 6 0.04 0.03 6 0.05 0.03 6 0.03 0.02 6 0.03 0.94
Docosapentaenoic acid, g/d 0.02 6 0.01 0.01 6 0.02 0.02 6 0.02 0.02 6 0.01 0.37
DHA, g/d 0.06 6 0.08 0.06 6 0.10 0.06 6 0.07 0.06 6 0.07 0.88
Reproductive hormones
Estradiol, pg/mL 111.3 6 39.6 110.0 6 40.9 113.0 6 37.0 110.7 6 41.3 0.88
Free estradiol, pg/mL 1.7 6 0.6 1.8 6 0.7 1.7 6 0.5 1.7 6 0.6 0.79
FSH, mIU/mL 6.4 6 2.2 6.1 6 1.9 6.4 6 2.3 6.7 6 2.3 0.11
LH, ng/mL 9.5 6 3.1 9.1 6 2.7 9.5 6 3.0 9.9 6 3.5 0.19
Luteal progesterone,4 ng/mL 7.1 6 3.3 7.0 6 3.6 7.3 6 3.1 7.0 6 3.2 0.52
SHBG, nmol/L 48.0 6 21.0 45.3 6 18.3 51.2 6 22.1 47.5 6 22.2 0.18
Testosterone, ng/dL 30.2 6 10.0 29.6 6 8.6 29.8 6 10.2 31.4 6 11.1 0.67
Free testosterone, ng/dL 0.4 6 0.1 0.4 6 0.1 0.4 6 0.1 0.5 6 0.2 0.30
Free androgen index 2.7 6 1.6 2.7 6 1.3 2.4 6 1.1 3.0 6 2.2 0.10
1Six women were missing information on parity and 4 were missing information on past OC use. FSH, follicle stimulating hormone; LH, luteinizing
hormone; OC, oral contraceptive; SHBG, sex hormone–binding globulin.
2P values were based on ANOVA or Fisher’s exact test, where appropriate, and for reproductive hormones were based on the mean of the log hormone
concentrations.
3Mean 6 SD (all such values).
4Mean concentrations of measurements during the luteal-phase visits.
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TABLE 2
Association between specific fatty acids and reproductive hormone concentrations in healthy premenopausal women1
Total energy substitution model2 Carbohydrate substitution model3
Type of fat Tertile 2 vs. tertile 14 Tertile 3 vs. tertile 1 P-trend4 Tertile 2 vs. tertile 1 Tertile 3 vs. tertile 1 P-trend4
Total fat, % of energy
Estradiol, pg/mL 21.9 (27.6, 4.2) 23.5 (29.4, 2.8) 0.27 22.1 (27.9, 4.0) 23.8 (29.8, 2.5) 0.23
Free estradiol, pg/mL 22.8 (28.4, 3.1) 23.6 (29.4, 2.5) 0.26 23.0 (28.5, 2.9) 23.8 (29.7, 2.3) 0.23
FSH, mIU/mL 1.5 (23.4, 6.7) 2.7 (22.6, 8.2) 0.32 1.6 (23.3, 6.9) 2.9 (22.4, 8.5) 0.29
LH, ng/mL 22.4 (28.5, 4.1) 5.0 (21.9, 12.4) 0.12 22.4 (28.5, 4.2) 5.0 (22.0, 12.4) 0.12
Progesterone,5 ng/mL 211.0 (224.6, 5.0) 213.7 (227.3, 2.5) 0.10 211.5 (225.0, 4.5) 214.4 (228.0, 1.8) 0.09
SHBG, nmol/L 22.4 (26.9, 2.3) 20.3 (25.3, 4.9) 0.65 21.6 (25.4, 2.3) 20.2 (24.3, 4.1) 0.99
Testosterone, ng/dL 1.4 (21.5, 4.4) 4.0 (0.7, 7.3)* 0.01* 1.6 (21.3, 4.6) 4.2 (0.9, 7.6)* 0.01*
Free testosterone, ng/dL 0.7 (22.6, 4.0) 4.1 (0.5, 7.7)* 0.02* 0.8 (22.4, 4.2) 4.3 (0.7, 7.9)* 0.02*
Free androgen index 1.2 (23.6, 6.3) 4.3 (21.1, 10.0) 0.11 1.3 (23.6, 6.5) 4.4 (21.0, 10.1) 0.10
Saturated fat, % of energy
Estradiol, pg/mL 20.2 (26.1, 6.1) 23.2 (29.5, 3.6) 0.27 20.9 (27.2, 5.8) 24.4 (211.6, 3.4) 0.21
Free estradiol, pg/mL 0.3 (25.5, 6.5) 23.6 (25.5, 6.5) 0.17 0.3 (26.0, 6.9) 23.8 (210.9, 3.8) 0.18
FSH, mIU/mL 20.7 (25.6, 4.4) 20.8 (26.2, 4.9) 0.87 20.9 (26.2, 4.6) 20.9 (27.0, 5.8) 0.93
LH, ng/mL 22.4 (28.6, 4.2) 2.4 (24.7, 10.1) 0.24 21.5 (28.2, 5.7) 4.4 (24.0, 13.4) 0.11
Progesterone, ng/mL 0.1 (215.4, 18.4) 213.2 (227.5, 4.1) 0.07 9.6 (28.3, 31.1) 0.0 (218.8, 23.1) 0.48
SHBG, nmol/L 21.1 (24.9, 2.9) 0.8 (23.5, 5.4) 0.45 22.9 (26.9, 1.3) 22.0 (26.8, 3.1) 0.99
Testosterone, ng/dL 20.2 (23.1, 2.8) 0.1 (23.2, 3.6) 0.90 0.1 (23.0, 3.4) 0.9 (23.0, 4.8) 0.62
Free testosterone, ng/dL 20.6 (23.8, 2.7) 20.5 (24.2, 3.4) 0.92 0.0 (23.4, 3.6) 0.8 (23.3, 5.2) 0.63
Free androgen index 20.3 (25.2, 4.8) 21.2 (26.7, 4.6) 0.68 1.4 (23.8, 7.0) 1.9 (24.4, 8.8) 0.71
Monounsaturated fat, %
of energy
Estradiol, pg/mL 20.4 (26.4, 5.9) 22.4 (28.4, 4.1) 0.44 1.3 (25.4, 8.4) 0.8 (27.7, 10.0) 0.90
Free estradiol, pg/mL 21.2 (26.9, 4.9) 23.1 (29.0, 3.0) 0.31 0.3 (26.1, 7.3) 20.3 (28.4, 8.7) 0.94
FSH, mIU/mL 2.9 (22.2, 8.3) 3.5 (21.9, 9.1) 0.23 3.4 (22.3, 9.4) 3.3 (23.9, 11.1) 0.44
LH, ng/mL 0.4 (26.1, 7.3) 1.7 (25.1, 8.9) 0.61 20.9 (28.0, 6.6) 21.9 (210.7, 7.8) 0.69
Progesterone, ng/mL 4.3 (211.8, 23.2) 218.1 (231.1, 22.6)* 0.01* 9.4 (29.0, 31.7) 210.9 (229.6, 12.9) 0.24
SHBG, nmol/L 0.3 (23.6, 4.3) 3.1 (21.0, 7.6) 0.11 0.7 (23.7, 5.2) 3.7 (22.2, 9.7) 0.19
Testosterone, ng/dL 1.6 (21.4, 4.6) 2.5 (20.7, 5.8) 0.13 1.4 (22.0, 4.8) 1.1 (23.1, 5.5) 0.68
Free testosterone, ng/dL 1.5 (21.8, 4.9) 2.0 (21.5, 5.7) 0.27 1.6 (22.1, 5.4) 1.2 (23.5, 6.2) 0.70
Free androgen index 1.3 (23.6, 6.5) 0.6 (24.5, 6.1) 0.86 1.9 (23.6, 7.8) 0.9 (26.2, 8.5) 0.87
Polyunsaturated fat, %
of energy
Estradiol, pg/mL 20.9 (26.6, 5.1) 20.2 (26.2, 6.2) 0.98 21.6 (27.3, 4.4) 22.3 (28.8, 4.6) 0.52
Free estradiol, pg/mL 20.3 (25.9, 5.7) 20.7 (26.6, 5.4) 0.81 20.7 (26.4, 5.4) 21.7 (28.1, 5.2) 0.62
FSH, mIU/mL 3.5 (21.5, 8.7) 4.1 (21.2, 9.5) 0.15 3.5 (21.6, 8.8) 3.8 (22.1, 9.9) 0.24
LH, ng/mL 1.4 (24.8, 8.1) 6.4 (20.4, 13.7) 0.06 1.6 (24.8, 8.4) 7.3 (20.4, 15.5) 0.06
Progesterone, ng/mL 8.9 (27.6, 28.3) 8.8 (28.2, 28.9) 0.37 12.7 (24.5, 33.1) 18.8 (21.5, 43.2) 0.08
SHBG, nmol/L 0.8 (22.9, 4.7) 2.8 (21.2, 7.0) 0.16 0.2 (23.5, 4.1) 1.0 (23.4, 5.5) 0.65
Testosterone, ng/dL 1.3 (21.5, 4.3) 3.7 (0.6, 6.8)* 0.02* 1.4 (21.5, 4.4) 4.2 (0.8, 7.8)* 0.01*
Free testosterone, ng/dL 1.6 (21.5, 4.8) 4.0 (0.5, 7.5)* 0.02* 1.8 (21.4, 5.1) 4.7 (0.9, 8.7)* 0.01*
Free androgen index 1.8 (23.0, 6.8) 2.6 (22.5, 8.0) 0.32 2.3 (22.4, 7.5) 4.4 (21.3, 10.4) 0.14
v-3s, % of energy
Estradiol, pg/mL 20.7 (26.2, 5.1) 2.7 (23.4, 9.3) 0.38 0.1 (25.9, 6.4) 3.0 (24.4, 11.1) 0.40
Free estradiol, pg/mL 22.0 (27.3, 3.7) 2.9 (23.1, 9.3) 0.32 21.0 (26.8, 5.2) 4.3 (23.1, 12.3) 0.22
FSH, mIU/mL 1.5 (23.2, 6.4) 1.5 (23.6, 6.9) 0.58 0.6 (24.5, 5.9) 20.4 (26.5, 6.1) 0.88
LH, ng/mL 7.6 (1.2, 14.3)* 7.5 (0.6, 14.9)* 0.04* 5.7 (21.1, 12.9) 4.3 (23.8, 13.1) 0.36
Progesterone, ng/mL 14.2 (22.7, 34.0) 18.9 (0.4, 40.6) 0.05 15.0 (22.9, 36.2) 20.1 (22.2, 47.3) 0.09
SHBG, nmol/L 1.5 (22.0, 5.2) 21.6 (25.5, 2.4) 0.41 1.8 (22.0, 5.8) 22.1 (26.7, 2.7) 0.32
Testosterone, ng/dL 1.7 (21.0, 4.5) 3.6 (0.5, 6.8)* 0.02* 0.7 (22.2, 3.7) 2.1 (21.5, 5.9) 0.25
Free testosterone, ng/dL 1.5 (21.5, 4.6) 4.9 (1.4, 8.4)* 0.01* 0.4 (22.8, 3.7) 3.3 (20.9, 7.5) 0.11
Free androgen index 0.1 (24.3, 4.8) 5.9 (0.6, 11.4)* 0.02* 21.1 (25.8, 3.9) 4.5 (21.7, 11.1) 0.12
v-6s, % of energy
Estradiol, pg/mL 20.6 (26.2, 5.4) 0.0 (25.9, 6.4) 0.96 21.2 (27.1, 5.0) 21.7 (29.0, 6.3) 0.69
Free estradiol, pg/mL 20.1 (25.6, 5.9) 20.7 (26.5, 5.5) 0.82 20.9 (26.8, 5.2) 22.7 (29.8, 5.0) 0.48
FSH, mIU/mL 3.0 (21.8, 8.2) 3.7 (21.5, 9.1) 0.19 2.3 (22.9, 7.7) 1.8 (24.6, 8.7) 0.65
LH, ng/mL 0.7 (25.4, 7.1) 6.2 (20.5, 13.4) 0.06 20.9 (27.2, 6.0) 2.7 (25.5, 11.7) 0.47
Progesterone, ng/mL 10.6 (26.1, 30.2) 7.9 (28.9, 27.8) 0.45 13.4 (24.4, 34.4) 13.3 (28.2, 40.1) 0.30
SHBG, nmol/L 1.6 (22.0, 5.4) 2.2 (21.8, 6.4) 0.30 2.0 (21.9, 6.1) 2.9 (22.2, 8.2) 0.29
Testosterone, ng/dL 1.4 (21.4, 4.3) 3.8 (0.7, 6.9)* 0.01* 1.0 (22.0, 4.1) 3.1 (20.7, 7.1) 0.10
Free testosterone, ng/dL 1.5 (21.5, 4.7) 4.0 (0.6, 7.6)* 0.02* 0.9 (22.4, 4.3) 2.8 (21.5, 7.3) 0.19
Free androgen index 1.1 (23.5, 6.0) 2.7 (22.4, 8.0) 0.29 0.2 (24.7, 5.3) 0.9 (25.4, 7.6) 0.77
(Continued)
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Total energy substitution model2 Carbohydrate substitution model3
Type of fat Tertile 2 vs. tertile 14 Tertile 3 vs. tertile 1 P-trend4 Tertile 2 vs. tertile 1 Tertile 3 vs. tertile 1 P-trend4
trans Fat, % of energy
Estradiol, pg/mL 1.1 (24.9, 7.5) 20.5 (26.6, 6.0) 0.83 1.6 (24.5, 8.2) 20.1 (26.9, 7.3) 0.92
Free estradiol, pg/mL 0.2 (25.6, 6.4) 20.5 (26.5, 5.8) 0.85 1.0 (25.0, 7.4) 0.7 (26.1, 7.9) 0.87
FSH, mIU/mL 3.4 (21.7, 8.8) 0.8 (24.3, 6.2) 0.90 3.4 (21.9, 8.9) 0.2 (25.5, 6.3) 0.93
LH, ng/mL 3.9 (22.7, 11.0) 1.0 (25.5, 8.0) 0.88 4.2 (22.6, 11.3) 1.8 (25.6, 9.9) 0.71
Progesterone, ng/mL 27.3 (221.6, 9.5) 216.7 (229.7, 21.2)* 0.03* 22.8 (218.0, 15.4) 26.9 (223.2, 12.7) 0.46
SHBG, nmol/L 1.1 (22.8, 5.1) 2.0 (22.1, 6.3) 0.35 0.4 (23.5, 4.4) 20.4 (24.8, 4.2) 0.83
Testosterone, ng/dL 1.5 (21.5, 4.6) 2.3 (20.8, 5.5) 0.15 1.7 (21.2, 4.8) 3.1 (20.3, 6.7) 0.08
Free testosterone, ng/dL 1.3 (22.0, 4.7) 1.5 (21.9, 5.0) 0.42 1.7 (21.6, 5.1) 2.7 (21.1, 6.7) 0.17
Free androgen index 20.2 (25.1, 4.9) 20.4 (25.4, 4.9) 0.88 0.6 (24.3, 5.9) 2.1 (23.6, 8.1) 0.47
a-Linolenic acid, g/d
Estradiol, pg/mL 20.4 (26.3, 5.9) 0.6 (26.3, 7.9 ) 0.84 20.6 (26.5, 5.8) 0.0 (26.9, 7.5) 0.96
Free estradiol, pg/mL 1.8 (24.1, 8.1) 1.8 (25.0, 9.2) 0.64 1.8 (24.2, 8.1) 1.8 (25.2, 9.2) 0.66
FSH, mIU/mL 2.3 (22.7, 7.7) 2.3 (23.4, 8.5) 0.50 2.4 (22.7, 7.9) 2.1 (23.8, 8.4) 0.57
LH, ng/mL 5.4 (211.8, 12.6) 7.6 (20.2, 16.1) 0.08 5.2 (21.6, 12.4) 7.4 (20.6, 16.0) 0.09
Progesterone, ng/mL 11.3 (26.0, 31.8) 20.8 (218.3, 20.4) 0.75 12.6 (24.8, 33.1) 2.3 (215.8, 24.5) 0.99
SHBG, nmol/L 24.0 (27.7, 20.2)* 23.2 (27.6, 1.2) 0.25 24.1 (27.8, 20.3)* 24.0 (28.2, 0.5) 0.14
Testosterone, ng/dL 20.1 (23.1, 2.8) 2.8 (20.6, 6.5) 0.07 20.1 (23.1, 2.9) 2.7 (20.8, 6.4) 0.08
Free testosterone, ng/dL 1.7 (22.2, 4.4) 5.2 (1.3, 9.3)* 0.01* 1.1 (22.2, 4.5) 5.3 (1.3, 9.4)* 0.01*
Free androgen index 4.0 (21.0, 9.3) 8.2 (2.1, 14.6)* 0.01* 4.1 (21.0, 9.4) 8.8 (2.6, 15.3)* 0.01*
EPA, g/d
Estradiol, pg/mL 21.9 (27.5, 4.1) 5.9 (20.5, 12.6) 0.02* 22.0 (27.8, 4.3) 5.5 (21.3, 12.9) 0.03*
Free estradiol, pg/mL 21.5 (27.0, 4.4) 6.1 (20.1, 12.6) 0.02* 21.3 (27.0, 4.9) 6.4 (20.4, 13.7) 0.02*
FSH, mIU/mL 21.2 (25.9, 3.9) 21.6 (26.6, 3.6) 0.60 21.2 (26.2, 4.1) 21.9 (27.2, 3.9) 0.59
LH, ng/mL 20.9 (27.0, 5.7) 0.8 (25.6, 7.8) 0.70 21.0 (27.4, 5.9) 1.2 (25.9, 8.9) 0.60
Progesterone, ng/mL 215.2 (227.9, 20.2)* 19.4 (1.2, 40.9)* 0.002* 212.8 (226.2, 3.1) 22.1 (1.9, 46.4)* 0.001*
SHBG, nmol/L 2.0 (21.8, 5.9) 20.1 (24.1, 4.1) 0.62 1.9 (22.0, 6.0) 20.3 (24.6, 4.2) 0.53
Testosterone, ng/dL 1.6 (21.3, 4.6) 1.1 (22.0, 4.3) 0.72 2.0 (21.0, 5.1) 1.9 (21.5, 5.3) 0.50
Free testosterone, ng/dL 1.4 (21.8, 4.7) 1.4 (22.0, 4.9) 0.56 1.8 (21.5, 5.3) 2.2 (21.5, 6.2) 0.38
Free androgen index 0.3 (24.4, 5.3) 1.3 (23.8, 6.6) 0.62 0.8 (24.1, 6.1) 2.1 (23.5, 8.0) 0.48
Docosapentaenoic acid, g/d
Estradiol, pg/mL 22.5 (28.2, 3.6) 2.2 (24.1, 9.1) 0.33 23.1 (28.9, 3.1) 1.1 (26.1, 8.9) 0.55
Free estradiol, pg/mL 21.4 (27.0, 4.6) 0.9 (25.4, 7.5) 0.68 21.7 (27.5, 4.5) 0.1 (26.9, 7.7) 0.86
FSH, mIU/mL 20.7 (25.5, 4.4) 3.3 (22.2, 9.0) 0.16 20.1 (25.2, 5.1) 4.4 (21.8, 11.1) 0.11
LH, ng/mL 20.5 (26.8, 6.2) 0.5 (26.2, 7.8) 0.83 20.4 ( 26.9, 6.5) 1.1 (26.8, 9.5) 0.74
Progesterone, ng/mL 10.3 (26.5, 30.1) 20.0 (0.5, 43.2)* 0.05* 13.7 (24.2, 34.9) 27.3 (3.8, 55.9)* 0.03*
SHBG, nmol/L 20.5 (24.3, 3.5) 1.0 (23.2, 5.4) 0.56 20.8 (24.6, 3.3) 0.6 (24.2, 5.5) 0.72
Testosterone, ng/dL 22.7 (25.4, 0.2) 21.0 (24.1, 2.2) 0.86 22.5 (25.4, 0.5) 20.4 (24.0, 3.4) 0.84
Free testosterone, ng/dL 22.7 (25.8, 0.5) 21.3 (24.8, 2.2) 0.72 22.5 (25.7, 0.8) 20.8 (24.8, 3.4) 0.98
Free androgen index 22.5 (27.1, 2.4) 22.3 (27.4, 3.1) 0.51 22.3 (27.1, 2.8) 21.8 (27.7, 4.4) 0.67
DHA, g/d
Estradiol, pg/mL 21.5 (27.1, 4.6) 5.4 (21.1, 12.4) 0.04* 21.5 (27.4, 4.8) 4.9 (22.1, 12.4) 0.07
Free estradiol, pg/mL 20.8 (26.5, 5.2) 5.3 (21.1, 12.1) 0.05* 20.4 (26.3, 5.8) 5.4 (21.5, 12.9) 0.07
FSH, mIU/mL 1.3 (23.6, 6.5) 0.3 (24.9, 5.8) 0.96 1.3 (23.8, 6.7) 0.5 (25.2, 6.5) 0.99
LH, ng/mL 21.5 (27.6, 5.0) 1.3 (25.4, 8.5) 0.55 21.6 (28.0, 5.2) 1.7 (25.6, 9.6) 0.48
Progesterone, ng/mL 28.6 (222.4, 7.6) 18.2 (20.5, 40.4) 0.01* 25.0 (219.7, 12.5) 21.7 (0.7, 46.8)* 0.01*
SHBG, nmol/L 0.0 (23.8, 3.9) 21.0 (25.1, 3.3) 0.59 20.5 (24.4, 3.5) 21.3 (25.6, 3.3) 0.57
Testosterone, ng/dL 1.7 (21.3, 4.7) 2.3 (20.9, 5.7) 0.21 1.9 (21.1, 5.0) 3.3 (20.2, 6.8) 0.10
Free testosterone, ng/dL 1.5 (21.7, 4.9) 2.4 (21.2, 6.1) 0.24 1.9 (21.4, 5.4) 3.3 (20.6, 7.3) 0.13
Free androgen index 1.4 (23.4, 6.5) 2.4 (22.9, 8.1) 0.41 2.1 (23.0, 7.4) 3.4 (22.5, 9.4) 0.32
1Values are percentage changes with 95% CIs in parentheses. Linear mixed models with random intercepts were used to evaluate associations between
average dietary fat intake (as percentage of energy for each type of fat) across the cycle (averages calculated on the basis of up to 4 recalls/cycle) and log
serum concentrations of reproductive hormones at each cycle visit. The models took repeated measures into account and included up to 16 hormone
concentrations/participant (up to 8/cycle) for a total of 3899 study visits with dietary intake and hormone concentrations. *P , 0.05. FSH, follicle stimulating
hormone; LH, luteinizing hormone; ref, reference; SHBG, sex hormone–binding globulin.
2Adjusted for age, race, BMI, and total energy intake.
3Adjusted for age, race, BMI, and total energy intake, plus intake for the remaining types of fat (saturated, monounsaturated, polyunsaturated, and trans
fat) and protein intake.
4Calculated with the median intake of fat in each tertile as a continuous variable.
5Includes only measurements of progesterone during the luteal phase.
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consuming low-fat and high-fiber diets (17, 31) and with stud-
ies that observed increases in testosterone and dehydroepian-
drosterone sulfate in women consuming high-fat diets (32, 33).
Not all previous studies observed associations with androgens
(12, 15, 19, 20, 34) or found associations in the other direction
(decreased testosterone with high fat intakes) (35). Our results
connecting total fat, PUFAs, and androgens are consistent with
hypotheses that fatty acids positively influence steroidogenesis.
Specifically, v-6 fatty acids are precursors for prostaglandin
synthesis and can modulate the expression of key enzymes in-
volved in prostaglandin and steroid metabolism (2). A small
hospital-based study showed that plasma v-6 PUFAs were as-
sociated with increased androgens, although supplementation
with v-3 PUFAs decreased the concentrations of bioavailable
testosterone (36). Although we observed increases in androgens
with increasing v-3 PUFAs, this may suggest that the ratio of
these 2 fatty acids is important to consider in this relation.
However, when we evaluated the ratio we observed no associ-
ations with total testosterone concentrations (third tertile com-
pared with first tertile percentage change: 4.0%; 95% CI: 2.6%,
3.6%; P-trend = 0.65). Furthermore, in women with certain
ovulatory disorders, specifically polycystic ovary syndrome,
PUFAs have been shown to improve metabolic and endocrine
characteristics, although improvements in ovulation have not
been evaluated directly (37). The clinical implications of subtle
associations between dietary fats and testosterone concentra-
tions remain unknown to date and indeed may be different in
other populations, such as women with chronic anovulation or
other reproductive disorders. It may also be that these subtle
changes in testosterone concentrations may not be clinically
relevant, because it has been observed that women with clinical
hirsutism may have serum testosterone concentrations within the
normal range and conversely that women without a complaint of
hirsutism may have elevated testosterone concentrations (38,
39). Thus, relations between fatty acids and androgen synthesis,
including the effects in populations with a wider range of hor-
monal fluctuations or gynecologic disorders, effects of dietary
interventions, and Mendelian randomization studies to aid
causal inference (40, 41) merit further study and our results
highlight the potential for dietary components to modulate
hormone metabolism.
The lack of association with estradiol in the present study is
consistent with much of the previous literature (12–20). A study
in the Nurses’ Health Study II cohort found no associations
between fat intake and estradiol concentrations in 595 pre-
menopausal women; the researchers also concluded that no
strong, consistent associations exist in the literature (19). Typi-
cally, intervention trials have evaluated the impact of a diet low
in fat and high in fiber and found reduced estradiol concentra-
tions in response (13–15, 17, 18). However, not all of the studies
observed significant effects or evaluated fat independent of fiber,
and the overall evidence can be considered weak (16, 19). With
respect to dietary assessment tools, others relied on food-fre-
quency questionnaires, instead of multiple 24-h recalls as in the
present study, and had fewer measures across the cycle (typi-
cally 3) and were generally timed by cycle day. Previously, we
observed that high-fiber diets were associated with reduced es-
tradiol concentrations in the BioCycle Study (42). Interestingly,
in studies that tried to distinguish the effects of fat compared
with fiber, it appears that high fiber intake may drive the re-
duction in estradiol concentrations (17), although others con-
cluded that fat affects estrogen metabolism more than fiber (13).
Further supporting the independent role of fiber in altering es-
tradiol concentrations, we found no effects of dietary fatty acid
intake on estradiol concentrations, and additional adjustment for
fiber intake did not appreciably alter our estimates (results not
shown).
The literature that describes relations between dietary fats and
hormones, such as LH and FSH, is more limited, although a few
studies commented on fat intake and menstrual cycle length and
TABLE 3
Association between substitution of specific fatty acids for other types of fats and risk of anovulation and log-transformed reproductive hormone
concentrations in healthy premenopausal women1
Substitution of trans fat with Substitution of v-3s with
Outcome SFAs MUFAs v-3s SFAs MUFAs trans Fat
Anovulation2 1.24 (0.77, 1.97) 1.23 (0.74, 2.02) 0.80 (0.30, 2.14) 1.54 (0.55, 4.33) 1.53 (0.58, 4.06) 1.25 (0.47, 3.34)
Estradiol,3 pg/mL 21.0 (24.4, 2.4) 23.5 (27.4, 0.6) 23.8 (213.8, 7.5) 2.8 (27.9, 14.9) 0.3 (210.1, 11.9) 3.9 (26.9, 16.1)
FSH,3 mIU/mL 1.0 (21.9, 3.9) 0.6 (22.8, 4.1) 22.4 (211.0, 7.1) 3.4 (25.7, 13.4) 3.0 (26.0, 12.9) 2.4 (26.6, 12.3)
LH,3 ng/mL 20.8 (24.4, 2.9) 0.2 (24.1, 4.7) 29.7 (219.8, 1.7) 9.8 (22.5, 23.8) 10.9 (21.4, 24.8) 10.7 (21.7, 24.7)
Progesterone,3,4 ng/mL 25.9 (214.1, 3.2) 26.6 (216.4, 4.3) 222.4 (242.0, 4.0) 21.3 (29.6, 62.7) 20.3 (210.1, 60.9) 28.8 (23.8, 72.5)
SHBG,3 nmol/L 0.4 (21.7, 2.7) 21.2 (23.8, 1.5) 6.6 (20.9, 14.7) 25.8 (212.4, 1.4) 27.3 (213.7, 20.5)* 26.2 (212.8, 0.9)
Free testosterone,3 ng/dL 0.03 (21.8, 1.9) 1.1 (21.1, 3.4) 22.8 (29.5, 3.3) 2.9 (23.1, 9.2) 4.0 (21.9, 10.3) 2.9 (23.2, 9.2)
Free androgen index3 20.4 (23.1, 2.4) 1.4 (21.9, 4.9) 26.8 (215.0, 2.2) 6.9 (22.5, 17.1) 8.8 (20.5, 19.0) 7.3 (22.1, 17.6)
1Linear mixed models with random intercepts were used to evaluate associations with reproductive hormones, and multivariable RR estimation by
Poisson regression with robust error variance was used to estimate RRs for anovulation induced by substituting 1 type of fat for another by modeling the intake
of specific fats as continuous variables and calculating the difference in coefficients and the covariance matrix to estimate CIs. The average dietary fat intake
(as a percentage of energy for each type of fat) across the cycle was calculated on the basis of up to 4 recalls/cycle. The models take repeated measures into
account and included up to 16 hormone concentrations/participant (up to 8/cycle) for a total of 3899 study visits with dietary intake and hormone
concentrations. Models were adjusted for age, race, BMI, and total energy intake. *P , 0.05. FSH, follicle stimulating hormone; LH, luteinizing hormone;
SHBG, sex hormone–binding globulin.
2Values are RRs; 95% CIs in parentheses.
3Values are percentage changes; 95% CIs in parentheses.
4Includes only measurements of progesterone during the luteal phase.
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phase lengths (9, 10). Overall, these small studies generally found
that greater fat intakes improved menstrual cycle characteristics,
but the relation between fat intake and LH and FSH is in-
consistent, making comparisons with our results difficult (9, 10,
34). These previous studies tended to be small and did not control
for total energy intake or potential confounding. Larger studies
that elucidate the impact of dietary fat intake on the gonado-
tropin-steroid hormone profile and the consequent effects on
menstrual cycle function are warranted.
In general, data on the association between fat intake and
ovulation are limited. Here we observed that docosapentaenoic
acid was associated with a lower risk of anovulation, although no
other associations between fatty acid intakes and risk of anov-
ulation were found. It may be that the associations we observed
TABLE 4
Associations between specific fatty acids and risk of anovulation in healthy premenopausal women1
Model 12 Model 23
Tertile Ovulatory, n Anovulatory, n (%) RR (95% CI) P-trend4 RR (95% CI) P-trend4
Total fat, % of energy
1 157 12 (7) 1 (Reference) 1 (Reference)
2 154 16 (9) 1.31 (0.61,2.80) 0.41 1.33 (0.62,2.89) 0.38
3 156 14 (8) 1.37 (0.64, 2.92) 1.41 (0.65, 3.04)
Saturated fat, % of energy
1 153 16 (9) 1 (Reference) 1 (Reference)
2 157 13 (8) 0.93 (0.44, 1.97) 0.75 0.82 (0.36, 1.91) 0.94
3 157 13 (8) 1.08 (0.50, 2.33) 0.87 (0.37, 2.04)
Monounsaturated fat, % of energy
1 157 12 (7) 1 (Reference) 1 (Reference)
2 156 14 (8) 1.12 (0.52, 2.43) 0.38 1.18 (0.49, 2.88) 0.46
3 154 16 (9) 1.34 (0.68, 2.67) 1.46 (0.53, 4.04)
Polyunsaturated fat, % of energy
1 154 15 (9) 1 (Reference) 1 (Reference)
2 157 14 (8) 0.87 (0.46, 1.68) 0.64 0.79 (0.42, 1.49) 0.29
3 156 13 (8) 0.84 (0.41, 1.73) 0.63 (0.27, 1.47)
v-3s, % of energy
1 154 15 (9) 1 (Reference) 1 (Reference)
2 157 13 (8) 0.92 (0.49, 1.72) 0.99 0.91 (0.43, 1.91) 0.85
3 156 14 (8) 0.81 (0.39, 1.67) 1.08 (0.44, 2.65)
v-6s, % of energy
1 154 15 (9) 1 (Reference) 1 (Reference)
2 156 14 (8) 0.92 (0.49, 1.72) 0.56 0.76 (0.40, 1.41) 0.11
3 157 13 (8) 0.81 (0.39, 1.67) 0.46 (0.18, 1.19)
trans Fat, % of energy
1 155 14 (8) 1 (Reference) 1 (Reference)
2 158 12 (7) 0.99 (0.48, 2.03) 0.65 0.97 (0.47, 1.99) 0.88
3 154 16 (9) 1.18 (0.56, 2.48) 1.06 (0.47, 2.37)
a-Linolenic acid
1 153 16 (9) 1 (Reference) 1 (Reference)
2 163 8 (5) 0.50 (0.22, 1.12) 0.21 0.49 (0.22, 1.13) 0.28
3 151 18 (11) 1.44 (0.73, 2.86) 1.37 (0.67, 2.78)
EPA
1 178 17 (9) 1 (Reference) 1 (Reference)
2 129 14 (10) 1.04 (0.54, 1.97) 0.38 1.01 (0.53, 1.91) 0.38
3 160 11 (6) 0.75 (0.36, 1.57) 0.71 (0.30, 1.67)
Docosapentaenoic acid
1 143 19 (12) 1 (Reference) 1 (Reference)
2 169 12 (7) 0.51 (0.26, 1.00) 0.13 0.48 (0.23, 0.98)* 0.09
3 155 11 (7) 0.53 (0.27, 1.05) 0.42 (0.18, 0.95)*
DHA
1 156 18 (10) 1 (Reference) 1 (Reference)
2 156 11 (7) 0.56 (0.30, 1.04) 0.54 0.53 (0.27, 1.03) 0.52
3 155 13 (8) 0.69 (0.35, 1.39) 0.62 (0.26, 1.50)
1Multivariable RR estimation by Poisson regression with robust error variance was used to estimate RRs and 95% CIs for the associations between
average dietary fat intake across the cycle and anovulation (cycle was the unit of analysis with a total of 509 cycles evaluated). *P , 0.05.
2Adjusted for age, race, BMI, and total energy intake.
3Adjusted for age, race, BMI, and total energy intake, plus intake for the remaining types of fat (saturated, monounsaturated, polyunsaturated, and trans
fat) and protein intake.
4Calculated with the median intake of fat in each tertile as a continuous variable.
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with total fat and PUFAs and testosterone concentrations are of
insufficient magnitude to affect ovulatory function. Indeed, our
observed associations with testosterone concentrations, but not
with anovulation, may suggest that these subtle associations do
not have clinical implications among healthy women, especially
given that the observed percentage changes were onlyw4% (in
comparison to the CV for testosterone of 33% in this study
population). There is strong evidence from animal studies that
suggests the importance of v-3 fatty acids in enhancing ovula-
tion, reducing the incidence of ovarian cysts, and improving
fertility, embryo quality, and pregnancy maintenance (3–5). In
addition, the Nurses’ Health Study II observed that PUFAs
tended to provide weak protection against ovulatory infertility
but only among women with high iron intakes (22). Their
finding that increased trans fat was associated with a greater
likelihood of developing ovulatory infertility is not inconsistent
with our results, because we observed a significant reduction in
progesterone concentrations in the total energy substitution
models and a nonsignificant trend toward a reduced risk of an-
ovulation when substituting trans fats with v-3s, although we
did not observe associations between trans fats and the relative
risk of anovulation. It may be that the intakes of trans fat in this
population were not sufficient to affect ovulation because la-
beling requirements for trans fatty acids in the United States
resulted in a substantial reduction in these fats in the American
food supply by the time the BioCycle Study was conducted.
The BioCycle Study has several strengths, including multiple
measures of hormones over 2 menstrual cycles (using stan-
dardized methods to time cycle phase) and multiple measures of
dietary fat intake among an ethnically diverse group of women.
Although self-report of diet is subject to measurement error, our
study used multiple validated 24-h dietary recalls to reduce the
potential for misclassification. Women were selected into the
BioCycle Study only if they were not planning to undertake
a special diet, which enhances the generalizability of our findings.
Indeed, the reported intake of fatty acids in the BioCycle Study
was similar to intakes observed among reproductive-aged women
in the United States according to the NHANES that was com-
pleted during the same time frame as the present study (mean
percentage of energy from fat: NHANES, 33.6%; BioCycle,
33.9%; mean percentage of energy from protein: NHANES,
15.2%; BioCycle, 15.7%; mean percentage of energy from
carbohydrates: NHANES, 50.4%; BioCycle, 50.8%). The mean
reported total calories consumed in NHANES was 1809, which is
slightly higher than reported in the BioCycle Study (43). The
prospective design and exclusion criteria followed for the Bio-
Cycle Study strengthen the ability to draw inferences by reducing
the potential for bias from known risk factors for anovulation.
These methods are an important improvement over previous
studies.
Nevertheless, the study faced several limitations, including the
absence of daily measures of progesterone or transvaginal ul-
trasounds to confirm ovulation. However, multiple well-timed
serum hormone measurements, along with the use of fertility
monitors that measured LH daily in urine, were used to aid in
classifying ovulatory cycles (28, 44). Last, the small number of
anovulatory cycles observed limited our power to detect subtle
effects of other dietary fatty acids, if such effects exist. The
accurate assessment of dietary exposures is especially chal-
lenging, because data are highly subject to measurement error,
particularly for long-chain marine PUFA intakes (within-woman
CVs ranged from 34% to 61%). However, multiple dietary recalls
have been shown to be valid measures of dietary exposures for
many nutrients (45–47), and based on the variability observed
here, our data suggest that we had a sufficient number of repeats
to adequately assess long-term nutrient intakes. It should be
noted that this study was exploratory and offers a comprehensive
and hypothesis-generating picture of the potential associations
between specific types of dietary fat and reproductive hormone
concentrations, although we cannot rule out the possibility that
some associations may be the result of multiple comparisons and
due to type 1 error. This study is also unique in that dietary
intake and hormone concentrations were assessed at the same
cycle visit, so as to reflect short-term effects of dietary intake on
reproductive function, thus limiting our ability to assess effects
on long-term outcomes.
In conclusion, we observed that total fat intakes, in particular
higher PUFA intakes, were associated with greater testosterone
concentrations, although the magnitude of the increase was very
small. The PUFA docosapentaenoic acid was not associated with
testosterone concentrations but was associated with increased
progesterone concentrations and a decreased risk of anovulation.
Neither total fat nor specific types of fat were associated with
other reproductive hormones or anovulation in this cohort of
healthy women without any known infertility. These results
suggest a role for fatty acids, specifically PUFAs, in androgen
synthesis, although future studies are needed to confirm these
findings and to allow us to better understand whether alterations
in androgen synthesis have implications for women’s fertility and
long-term reproductive health.
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